ICER Offers Drug Appraisals Without QALYs If Democrats Find The Metric Too Toxic

By John Wilkerson / July 8, 2021 at 2:04 PM
Editor's Note: An earlier version of this story said David Whitrap called many patient advocates "pharma front groups." He did not mention patient advocates in his statement. The headline and first paragraph also have been changed to clarify that ICER has always allowed policymakers the option of not using QALYs. The drug-appraisal nonprofit ICER is willing to exclude quality-adjusted life years ​from value assessments and rely on the other metrics it already uses to determine fair drug...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.